Nov 9, 2017 Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance Learn More
Nov 7, 2017 Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma Learn More
Nov 2, 2017 Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance Learn More